High Growth Tech Stocks In Asia For April 2025

In This Article:

The Asian market has been navigating a complex landscape marked by escalating trade tensions between the U.S. and China, which have led to increased tariffs and impacted global economic growth. Despite these challenges, high-growth tech stocks in Asia continue to capture investor interest due to their potential for innovation and resilience in adapting to shifting market conditions.

Top 10 High Growth Tech Companies In Asia

Name

Revenue Growth

Earnings Growth

Growth Rating

Fositek

31.52%

37.08%

★★★★★★

Xi'an NovaStar Tech

30.60%

36.56%

★★★★★★

Shanghai Baosight SoftwareLtd

20.81%

26.05%

★★★★★★

Shanghai Huace Navigation Technology

26.94%

24.43%

★★★★★★

eWeLLLtd

24.66%

25.31%

★★★★★★

Seojin SystemLtd

31.68%

39.34%

★★★★★★

giftee

21.13%

67.05%

★★★★★★

PharmaResearch

20.73%

27.75%

★★★★★★

Suzhou Gyz Electronic TechnologyLtd

27.52%

121.67%

★★★★★★

JNTC

34.26%

86.00%

★★★★★★

Click here to see the full list of 493 stocks from our Asian High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

RemeGen

Simply Wall St Growth Rating: ★★★★★★

Overview: RemeGen Co., Ltd. is a biopharmaceutical company focused on the discovery, development, and commercialization of biologics for treating autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States, with a market cap of approximately HK$23.62 billion.

Operations: RemeGen focuses on biopharmaceutical research, service, production, and sales, generating revenue of CN¥1.72 billion. The company operates primarily in Mainland China and the United States, addressing unmet medical needs in autoimmune, oncology, and ophthalmic diseases.

RemeGen, a key player in Asia's high-growth tech sector, is navigating through its developmental phase with strategic executive appointments and significant clinical advancements. Recently reporting a revenue surge to CNY 1.72 billion, up from CNY 1.08 billion the previous year, the company is on a robust growth trajectory with revenue expected to outpace the Hong Kong market's 8.2% annual growth at 23.2%. Despite current unprofitability, RemeGen's aggressive research and development focus, which remains central to its strategy, is set to position it for future profitability with an anticipated profit growth forecast significantly above market averages. The recent board changes and the breakthrough designation for Disitamab Vedotin underscore its commitment to innovation in oncology treatments, promising enhanced shareholder value as it transitions towards profitability over the next three years.